8-K: Geron Corporation Announces CEO Transition: John A. Scarlett Resigns, Dawn C. Bir Appointed Interim CEO

Geron Corporation announced the resignation of John A. Scarlett as President, CEO, and Chairman, and the appointment of Dawn C. Bir as Interim President and CEO, effective March 10, 2025.

Summary

• John A. Scarlett, M.D., concluded his service as President, Chief Executive Officer, and Chairman of the Board of Directors of Geron Corporation, effective March 10, 2025.
• Dr. Scarlett also resigned from the Board but will remain employed by the Company through March 31, 2025, to assist with the transition.
• Dawn C. Bir, a current member of the Board, was appointed as the Interim President and Chief Executive Officer of Geron, effective March 10, 2025.
• The Company is conducting a search for a permanent Chief Executive Officer.
• Ms. Bir has stepped down from the Compensation Committee and the Nominating and Corporate Governance Committee of the Board.
• Elizabeth G. O'Farrell, currently the Lead Independent Director of the Board, was appointed Chair of the Board, effective March 10, 2025.

Sentiment

Score: 5

Explanation: Neutral sentiment due to the executive transition. While the appointment of an interim CEO provides stability, the departure of the previous CEO introduces uncertainty.

Positives

• Dawn C. Bir brings extensive experience from previous roles at Reata Pharmaceuticals, Pharmacyclics LLC (an AbbVie company), McKesson Corporation, Genentech, Inc., and Bristol Myers Squibb Company.
• Elizabeth G. O'Farrell's appointment as Chair of the Board provides continuity and leadership.

Negatives

• The departure of the CEO creates uncertainty during the search for a permanent replacement.

Risks

• The transition period may pose challenges as the company seeks a new permanent CEO.
• Uncertainty regarding the future strategic direction of the company until a permanent CEO is appointed.

Future Outlook

The company will be searching for a permanent Chief Executive Officer.

Industry Context

Executive transitions are common in the biopharmaceutical industry, especially for companies in clinical development stages. The appointment of an interim CEO with commercial experience suggests a potential shift in focus towards market readiness.

Comparison to Industry Standards

• Interim CEO appointments are a standard practice in the biopharmaceutical industry during executive searches.
• Dawn Bir's experience at Reata Pharmaceuticals, which was acquired by Biogen, is a positive sign, as it demonstrates her ability to navigate the complexities of the pharmaceutical market.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders may experience short-term uncertainty due to the CEO transition.
• Employees may be affected by potential changes in strategic direction under new leadership.

Next Steps

• The Company will conduct a search for a permanent Chief Executive Officer.
• The Company may determine new compensatory arrangements for or grants or awards to be made to Ms. Bir in connection with her appointment as the Company's Interim President and Chief Executive Officer.

Key Dates